{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:55:30Z","timestamp":1791006930453,"version":"4.1.0"},"reference-count":30,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IRDR"],"published-print":{"date-parts":[[2026,8,31]]},"DOI":"10.5582\/irdr.2026.01017","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T22:13:23Z","timestamp":1783462403000},"page":"247-253","source":"Crossref","is-referenced-by-count":0,"title":["Cutaneous lymphomas reported following the use of dupilumab, nemolizumab, tralokinumab, or lebrikizumab: A case investigation based on JADER database and disproportionality analysis"],"prefix":"10.5582","volume":"15","author":[{"given":"Hiroyuki","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Practical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, Chiba, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Practical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, Chiba, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018; 4:1.","DOI":"10.1038\/s41572-018-0001-z"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Thibodeaux Q, Smith MP, Ly K, Beck K, Liao W, Bhutani T. A review of dupilumab in the treatment of atopic diseases. Hum Vaccin Immunother. 2019; 15:2129-2139.","DOI":"10.1080\/21645515.2019.1582403"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Dobos G, Pohrt A, Ram-Wolff C, Lebb\u00e9 C, Bouaziz JD, Battistella M, Bagot M, de Masson A. Epidemiology of cutaneous T-cell lymphomas: A systematic review and meta-analysis of 16,953 patients. Cancers (Basel). 2020; 12:2921.","DOI":"10.3390\/cancers12102921"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Hamada T, Iwatsuki K. Cutaneous lymphoma in Japan: A nationwide study of 1733 patients. J Dermatol. 2014; 41:3-10.","DOI":"10.1111\/1346-8138.12299"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Cabrera-Perez JS, Carey VJ, Odejide OO, Singh S, Kupper TS, Pillai SS, Weiss ST, Akenroye A. Integrative epidemiology and immunotranscriptomics uncover a risk and potential mechanism for cutaneous lymphoma unmasking or progression with dupilumab therapy. J Allergy Clin Immunol. 2025; 155:1584-1594.","DOI":"10.1016\/j.jaci.2024.10.028"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Lavin L, Dusza S, Geller S. Cutaneous T-cell lymphoma after dupilumab Use: A real-world pharmacovigilance study of the FDA adverse event reporting system. J Invest Dermatol. 2025; 145:211-214.e1.","DOI":"10.1016\/j.jid.2024.06.1272"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Pierog O, Bao A, Rozati S. The association of atopic dermatitis and cutaneous T-cell lymphoma: A multicentre cohort study. J Eur Acad Dermatol Venereol. 2025; 39:e172-e173.","DOI":"10.1111\/jdv.20243"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Basrai S, Gomez-Lara AR, Dahabreh D, De Feraudy S, Tsai EY, McCleskey PE. Mycosis fungoides unmasked by tralokinumab treatment for atopic dermatitis. JAAD Case Rep. 2025; 61:85-88.","DOI":"10.1016\/j.jdcr.2025.03.030"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Yang Z, Tang K, Chen J. Post-marketing safety of tralokinumab: A real-world pharmacovigilance study based on the FDA adverse event reporting system. Expert Opin Drug Saf. 2024; 23:1439-1446.","DOI":"10.1080\/14740338.2024.2410434"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Lu L, Feng J, He H, Peng Y, Zhang S, Yang L, Liu Y, Wang T. Cutaneous lymphoma associated with JAK inhibitors: A pharmacovigilance analysis of the FAERS database and literature review. Acta Derm Venereol. 2026; 106:adv44546.","DOI":"10.2340\/actadv.v106.44546"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Tanaka H, Ohyama K, Horikomi Y, Ishii T. Association between anaphylaxis and anti-influenza drug use: An analysis of the Japanese Adverse Drug Event Report database. Drug Discov Ther. 2021; 15:150-155.","DOI":"10.5582\/ddt.2021.01053"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013; 48:452-458.","DOI":"10.1038\/bmt.2012.244"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Chiba T, Nagai T, Osada SI, Manabe M. Diagnosis of mycosis fungoides following administration of dupilumab for misdiagnosed atopic dermatitis. Acta Derm Venereol. 2019; 99:818-819.","DOI":"10.2340\/00015555-3208"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Umemoto N, Demitsu T, Otaki K, Matsumoto T, Takazawa M, Yamada A, Kimura SI, Kakurai M. Dupilumab therapy in S\u00e9zary syndrome misdiagnosed as atopic dermatitis: A case report. J Dermatol. 2020; 47:e356-e357.","DOI":"10.1111\/1346-8138.15501"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Fujii K, Kawahira H, Hisadome M, Kanekura T. Development of mycosis fungoides with peripheral blood involvement after a single use of dupilumab. J Cutan Immunol Allergy. 2022; 5:188-189.","DOI":"10.1002\/cia2.12239"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Amagai M, Ozawa M, Amagai R, Ohuchi K, Muto Y, Kambayashi Y, Aiba S, Fujimura T. Nodal anaplastic large cell lymphoma with lymphomatoid papulosis following treatment of initially presumed atopic dermatitis with dupilumab: A case report. Dermatol Ther. 2022; 35:e15290.","DOI":"10.1111\/dth.15290"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Nishimura M, Kurihara Y, Miyahara M, Maruta Y, Akashi M, Ohshima K, Ono F, Nakahara T. A case of cutaneous CD30+ T-cell lymphoproliferative Disorder that developed during administration of dupilumab (Dupixent\u00ae). Nishinihon J Dermatol. 2023; 85:366-369.","DOI":"10.2336\/nishinihonhifu.85.366"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Fujii K, Yoshizaki A, Matsuoka A, Baba N, Ohshima K, Kanekura T. Progression of CD8-positive S\u00e9zary syndrome from mycosis fungoides following dupilumab treatment. Eur J Dermatol. 2024; 34:294-296.","DOI":"10.1684\/ejd.2024.4729"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Muramatsu K, Ikutama R, Hasegawa T. A case of S\u00e9zary syndrome in a patient treated with dupilumab for atopic dermatitis. Indian J Dermatol. 2024; 69:184-187.","DOI":"10.4103\/ijd.ijd_177_23"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Arora A, Jalali RK, Vohora D. Relevance of the Weber effect in contemporary pharmacovigilance of oncology drugs. Ther Clin Risk Manag. 2017; 13:1195-1203.","DOI":"10.2147\/TCRM.S137144"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Kim YS. Comparative efficacy and safety of tralokinumab and dupilumab in moderate-to-severe atopic dermatitis: A narrative review. J Clin Med. 2025; 14:4960.","DOI":"10.3390\/jcm14144960"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Mazzetto R, Miceli P, Tartaglia J, Ciolfi C, Sernicola A, Alaibac M. Role of IL-4 and IL-13 in cutaneous T cell lymphoma. Life (Basel). 2024; 14:245.","DOI":"10.3390\/life14020245"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Guglielmo A, Borghi A, Schettini N, Perillo M, Corazza M, Piraccini BM, Pileri A. Mycosis fungoides and IL-4\/13 inhibitors: What is known and unmet needs. Expert Rev Clin Immunol. 2025; 21:723-729.","DOI":"10.1080\/1744666X.2025.2507332"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Wan L, Park A, Lio P. Exploring the link between dupilumab and cutaneous T-cell lymphomas: A systematic review. Dermatitis. 2025; 36:568-574.","DOI":"10.1089\/derm.2024.0486"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Li M, Zhao W, Lai P, Xiao Y, Wang Y. Dupilumab-associated lymphoproliferative disorders: A comprehensive review on clinicohistopathologic features and underlying mechanisms. Curr Opin Immunol. 2025; 94:102563.","DOI":"10.1016\/j.coi.2025.102563"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Park A, Wong L, Lang A, Kraus C, Anderson N, Elsensohn A. Cutaneous T-cell lymphoma following dupilumab use: A systematic review. Int J Dermatol. 2023; 62:862-876.","DOI":"10.1111\/ijd.16388"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Olszewska B, \u017bawrocki A, Gle\u0144 J, Lakomy J, Karczewska J, Zab\u0142otna M, Malek M, Jankau J, Lange M, Biernat W, Nowicki RJ, Soko\u0142owska-Wojdy\u0142o M. Interleukin-31 is overexpressed in skin and serum in cutaneous T-cell lymphomas but does not correlate to pruritus. Postepy Dermatol Alergol. 2022; 39:81-87.","DOI":"10.5114\/ada.2020.100824"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Olszewska B, Soko\u0142owska-Wojdy\u0142o M, Lakomy J, Nowicki RJ. The ambiguous pruritogenic role of interleukin-31 in cutaneous T-cell lymphomas in comparison to atopic dermatitis: A review. Postepy Dermatol Alergol. 2020; 37:319-325.","DOI":"10.5114\/ada.2020.96260"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. van Santen S, Out JJ, Zoutman WH, Quint KD, Willemze R, Vermeer MH, Tensen CP. Serum and cutaneous transcriptional expression levels of IL31 are minimal in cutaneous T cell lymphoma variants. Biochem Biophys Rep. 2021; 26:101007.","DOI":"10.1016\/j.bbrep.2021.101007"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Ferretti E, Corcione A, Pistoia V. The IL-31\/IL-31 receptor axis: general features and role in tumor microenvironment. J Leukoc Biol. 2017; 102:711-717.","DOI":"10.1189\/jlb.3MR0117-033R"}],"container-title":["Intractable & Rare Diseases Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/15\/3\/15_2026.01017\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:35:27Z","timestamp":1791005727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/15\/3\/15_2026.01017\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5582\/irdr.2026.01017","relation":{},"ISSN":["2186-361X","2186-3644"],"issn-type":[{"value":"2186-361X","type":"electronic"},{"value":"2186-3644","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"2026.01017"}}